SAN DIEGO, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will be presenting a company overview at the 15th Annual BIO CEO & Investor Conference at 11:00 a.m. EST on Monday, February 11, 2013, at the Waldorf-Astoria Hotel in New York City.
About Fate Therapeutics, Inc.
Uniquely positioned at the intersection of stem cell science and orphan disease, Fate Therapeutics is pioneering the discovery and development of adult stem cell modulators in pursuit of innovative therapeutics with the potential to cure or transform the lives of patients with rare life-threatening disorders. The Company's lead program, ProHema, an innovative cord blood-derived cell therapy containing ex-vivo pharmacologically-modulated hematopoietic stem cells (HSCs), is currently in Phase 2 testing in patients with leukemia undergoing hematopoietic transplantation. The Company plans to pursue clinical evaluation of pharmacologically-modulated HSCs in patients with rare genetic disorders, an area of tremendous unmet medical need in which the curative potential of cord blood transplantation is well recognized. In addition, Fate Therapeutics is developing proprietary Wnt7a-based protein therapeutics that have shown efficacy in preclinical models of muscular dystrophy. To advance its discovery efforts, the Company applies its award-winning, proprietary, induced pluripotent stem cell technology to generate rare cell populations and model disease. Fate Therapeutics is headquartered in San Diego, CA, with a subsidiary in Ottawa, Canada. For more information, please visit www.fatetherapeutics.com.
CONTACT: Paul Cox, Stern Investor Relations, Inc. 212.362.1200, email@example.comSource:Fate Therapeutics, Inc